![](https://library.celltelligence.com/wp-content/uploads/2020/05/Allogene-Earnings.png)
$0
ALLO-501’s ALPHA2 Trial Progresses but EXPAND Study Might Experience Difficulties to Enroll; ALLO-316’s AACR Results Highlighted; Allogene Ready for Partnerships to Advance its Programs; Allogene’s Q1 2023 Earnings Call Summary
On Wednesday, May 3, Allogene held its Q1 2023 earnings call (press release / presentation) highlighting the progress made in ALLO-501A’s (allogeneic CD19 CAR-T) ALPHA2 trial while admitting that some clinical trial sites have declined to participate in the EXPAND trial due to its randomized design. Below, Celltelligence provides insights on the consequences of Allogene’s decision to include ALLO-647 (anti-CD52 mAb) in its lymphodepletion regimen for the administration of ALLO-501A and its other cell therapies while discussing potential plans to partner for the development of any of its cell therapy programs.